New brain scan agent could spot Parkinson's and MSA early

NCT ID NCT07604116

First seen May 25, 2026 · Last updated May 25, 2026

Summary

This early-phase study tests a new imaging drug called SST001 in 30 healthy adults and people with multiple system atrophy (MSA) or Parkinson's disease. The main goal is to check if SST001 is safe and how it spreads in the body using PET scans. Researchers hope it may help doctors see brain changes linked to these diseases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, 214122, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200040, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.